Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.65 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591218 | 1.00 | P2RX7 (0.65) | P2RX7CTSDTRPV1RPS6KB1CSF1R | |
| SCHEMBL1590130 | 1.00 | P2RX7 (0.65) | P2RX7CTSDTRPV1RPS6KB1CSF1R | |
| SCHEMBL1591099 | 0.93 | P2RX7 (0.63) | P2RX7CSF1RPDGFRBPDGFRA | |
| SCHEMBL1591105 | 0.93 | P2RX7 (0.63) | P2RX7CSF1RPDGFRBPDGFRA | |
| SCHEMBL1591694 | 0.93 | P2RX7 (0.63) | P2RX7CSF1RPDGFRBPDGFRA | |
| SCHEMBL1590583 | 0.90 | P2RX7 (0.80) | P2RX7TRPV1RPS6KB1CSF1RPDGFRB | |
| SCHEMBL1589987 | 0.90 | P2RX7 (0.80) | P2RX7TRPV1RPS6KB1CSF1RPDGFRB | |
| SCHEMBL1589983 | 0.90 | P2RX7 (0.80) | P2RX7TRPV1RPS6KB1CSF1RPDGFRB | |
| SCHEMBL1590648 | 0.90 | P2RX7 (0.56) | P2RX7TRPV1 | |
| SCHEMBL1590651 | 0.90 | P2RX7 (0.56) | P2RX7TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885CTSD 942/4885TRPV1 19/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885CTSD 942/4885TRPV1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.